Susan E Sharp1, Michael J Gelfand, Michael J Absalon. 1. Department of Radiology, MLC 5031, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH 45229-3039, USA. susan.sharp@cchmc.org
Abstract
BACKGROUND: Altered FDG uptake patterns were noted in certain lymphoblastic lymphoma patients during therapy. OBJECTIVE: To describe these altered FDG uptake patterns and their relationship to chemotherapy. MATERIALS AND METHODS: Thirty-five FDG PET or PET/CT scans obtained in 11 children with lymphoblastic lymphoma were retrospectively reviewed. FDG uptake patterns were recorded. SUV measurements were performed in liver and facial soft tissues. Results were correlated with induction chemotherapy regimens. RESULTS: Six of the children had transiently altered FDG uptake with increased uptake in the superficial soft tissues, most notably involving the face. Altered uptake was noted approximately 1 month after initiation of chemotherapy and subsequently resolved. Hepatic uptake was transiently reduced on the 1-month scan in all six children with increased facial uptake. No significant FDG uptake in lymphoma was seen on five of six scans with altered uptake; however, two of these five affected children had FDG uptake in lymphoma on the next follow-up examination. Blood glucose levels in the affected children were in the normal range. All six children with altered FDG uptake received the same induction chemotherapy regimen, which included very high doses of corticosteroids. CONCLUSIONS: Children with lymphoblastic lymphoma on induction chemotherapy protocols including very high doses of corticosteroids transiently demonstrated altered FDG uptake patterns, including increased superficial facial uptake and reduced hepatic uptake. The facial uptake is probably the FDG PET equivalent of Cushingoid facies. Caution in interpreting scans with this altered FDG uptake pattern is suggested, as uptake at sites of lymphomatous involvement may potentially be affected.
BACKGROUND: Altered FDG uptake patterns were noted in certain lymphoblastic lymphomapatients during therapy. OBJECTIVE: To describe these altered FDG uptake patterns and their relationship to chemotherapy. MATERIALS AND METHODS: Thirty-five FDG PET or PET/CT scans obtained in 11 children with lymphoblastic lymphoma were retrospectively reviewed. FDG uptake patterns were recorded. SUV measurements were performed in liver and facial soft tissues. Results were correlated with induction chemotherapy regimens. RESULTS: Six of the children had transiently altered FDG uptake with increased uptake in the superficial soft tissues, most notably involving the face. Altered uptake was noted approximately 1 month after initiation of chemotherapy and subsequently resolved. Hepatic uptake was transiently reduced on the 1-month scan in all six children with increased facial uptake. No significant FDG uptake in lymphoma was seen on five of six scans with altered uptake; however, two of these five affected children had FDG uptake in lymphoma on the next follow-up examination. Blood glucose levels in the affected children were in the normal range. All six children with altered FDG uptake received the same induction chemotherapy regimen, which included very high doses of corticosteroids. CONCLUSIONS:Children with lymphoblastic lymphoma on induction chemotherapy protocols including very high doses of corticosteroids transiently demonstrated altered FDG uptake patterns, including increased superficial facial uptake and reduced hepatic uptake. The facial uptake is probably the FDG PET equivalent of Cushingoid facies. Caution in interpreting scans with this altered FDG uptake pattern is suggested, as uptake at sites of lymphomatous involvement may potentially be affected.
Authors: J Moreno-Fernández; C Gutiérrez-Alcántara; M A Gálvez Moreno; L Jiménez-Reina; J P Castaño; P Benito-López Journal: J Clin Endocrinol Metab Date: 2008-09 Impact factor: 5.958
Authors: N A Shah; I A Urusova; A D'Agnolo; S D Colquhoun; B E Rosenbloom; S L Vener; S A Geller; M Younes; J Lechago; A P Heaney Journal: J Endocrinol Invest Date: 2007-04 Impact factor: 4.256
Authors: Mathias Fasshauer; Thomas Lincke; Helmut Witzigmann; Regine Kluge; Andrea Tannapfel; Michael Moche; Michael Buchfelder; Stephan Petersenn; Juergen Kratzsch; Ralf Paschke; Christian A Koch Journal: BMC Cancer Date: 2006-04-27 Impact factor: 4.430
Authors: Zvi Bar-Sever; Lorenzo Biassoni; Barry Shulkin; Grace Kong; Michael S Hofman; Egesta Lopci; Irina Manea; Jacek Koziorowski; Rita Castellani; Ariane Boubaker; Bieke Lambert; Thomas Pfluger; Helen Nadel; Susan Sharp; Francesco Giammarile Journal: Eur J Nucl Med Mol Imaging Date: 2018-10 Impact factor: 9.236